Obesity Patents (Class 514/909)
  • Patent number: 9034397
    Abstract: The present invention provides methods of administering a Dendrobium polyphenol in an amount effective to lower blood sugar, treat hepatic disease, obesity or diabetes. Exemplary hepatic disease includes fibrosis, fatty liver and hepatitis. Moreover, the Dendrobium polyphenol is extracted from the plants of the genus Dendrobium.
    Type: Grant
    Filed: October 30, 2013
    Date of Patent: May 19, 2015
    Assignee: Tunghai University
    Inventors: Chang-Chi Hsieh, Chin-Tung Wu, Jie-Yu Chen, Yi-Chieh Li, Hsin-Sheng Tsay
  • Patent number: 9029325
    Abstract: The invention relates to polypeptides comprising an amino acid sequence which is an analogue of pramlintide, pharmaceutical compositions comprising these polypeptides, and these polypeptides for use as medicaments.
    Type: Grant
    Filed: September 26, 2013
    Date of Patent: May 12, 2015
    Assignee: Novo Nordisk A/S
    Inventors: Lauge Schaeffer, Thomas Kruse, Henning Thoegersen
  • Patent number: 8957020
    Abstract: This invention relates to the use of nucleic acid sequences of the MAP kinase-interacting kinase (Mnk) gene family and amino acid sequences encoded thereby, and to using these sequences or effectors of Mnk nucleic acids or polypeptides, particularly Mnk kinase inhibitors and activators, in the diagnosis and treatment of diseases and disorders related to body-weight regulation and thermogenesis. One aspect of the disclosure encompasses methods of identifying an animal or human having an elevated probability of having or developing obesity, the method comprising: (a) obtaining a biological sample from an animal or human subject; and (b) determining from the biological sample whether the animal or human subject has a genetic variant of an Mnk2 and/or Mnk1 gene or a homolog thereof, or an expression product of said Mnk2 and/or Mnk1 gene or homolog thereof, wherein said genetic variant is associated with an elevated probability of having or developing obesity.
    Type: Grant
    Filed: September 26, 2011
    Date of Patent: February 17, 2015
    Assignee: Boehringer Ingelheim International GmbH
    Inventors: Arnd Steuernagel, Karsten Eulenberg, Guenter Broenner, Thomas Ciossek, Bettina Rudolph, Dorothea Rudolph, Funmi Belgore, Stefan Jaekel, Christoph Meyer
  • Patent number: 8921398
    Abstract: The present invention relates to compounds of general formula I, wherein R1, LP, HetAr, Ar, and n are as defined in the application, which have valuable pharmacological properties, and in particular bind to the GPR119 receptor and modulate its activity.
    Type: Grant
    Filed: June 6, 2012
    Date of Patent: December 30, 2014
    Assignee: Boehringer Ingelheim International GmbH
    Inventors: Armin Heckel, Frank Himmelsbach, Elke Langkopf, Bernd Nosse, Neil J. Ashweek, Nicole Harriott
  • Patent number: 8889660
    Abstract: In one aspect of the present invention, a pharmaceutical composition for treating a metabolic disease in a mammalian subject includes a therapeutically effective amount of (R)-all-trans-13,14-dihydroretinol and a pharmaceutically acceptable carrier or diluent. In another aspect of the present invention, pharmaceutical composition for treating a metabolic disease in a mammalian subject includes a therapeutically effective amount of (S)-all-trans-13,14-dihydroretinol and a pharmaceutically acceptable carrier or diluent. In a further aspect of the present invention, a method is provided for treating a metabolic disease in a mammalian subject. The method includes administering to the subject a pharmaceutical composition comprising at least one all-trans-13,14-dihydroretinoid, all-trans-13,14-dihydroretinoid derivative, or agent capable of modulating the level of at least one all-trans-13,14-dihydroretinoid or all-trans-13,14-dihydroretinoid derivative in the subject.
    Type: Grant
    Filed: November 16, 2012
    Date of Patent: November 18, 2014
    Assignee: Case Western Reserve University
    Inventors: Krzysztof Palczewski, Radu Moise
  • Patent number: 8859537
    Abstract: This invention relates to the use of a ligand of the 5-HT4 receptor or of a pharmaceutically acceptable salt of this ligand and to a nucleic acid coding for a 5-HT4 receptor or of a functionally equivalent receptor for a drug for treating and/or preventing a pathology associated with an obsessional behavior such as anorexia, bulimia and the addiction to drugs of abuse or obesity. The invention also relates to a method for identifying a compound that is biologically active in the treatment and/or the prevention of a pathology associated with an obsessional conduct or obesity including: a) placing the 5-HT4 receptor or a functionally equivalent receptor in contact with this biologically active compound, and b) the determination of whether this biologically active compound is capable of modulating the basal activity of the 5-HT4 receptor or of a functionally equivalent receptor.
    Type: Grant
    Filed: April 29, 2005
    Date of Patent: October 14, 2014
    Assignee: Centre National de la Recherche Scientifique-CNRS
    Inventor: Valerie Compan
  • Patent number: 8846724
    Abstract: Provided herein are methods and compositions for modulating the activity or level of a sirtuin, thereby treating or preventing obesity or an insulin resistance disorder, such as diabetes in a subject. Exemplary methods comprise contacting a cell with a sirtuin activating compound or an inhibitory compound to thereby increase or decrease fat accumulation, respectively.
    Type: Grant
    Filed: July 27, 2011
    Date of Patent: September 30, 2014
    Assignees: President and Fellows of Harvard College, The General Hospital Corporation
    Inventors: David A. Sinclair, Maria Alexander-Bridges
  • Patent number: 8815947
    Abstract: A method of increasing the insulin sensitivity of insulin resistant cells includes administering to the cells an amount of all-trans-retinoic acid effective to activate transcription factor perosixome proliferator-activated receptor (PPAR) ?/? of the cells.
    Type: Grant
    Filed: July 3, 2012
    Date of Patent: August 26, 2014
    Assignee: Case Western Reserve University
    Inventor: Noa Noy
  • Patent number: 8785458
    Abstract: The invention relates to a method for the treatment of obesity and related diseases comprising the administration of a therapeutically effective amount of Flibanserin.
    Type: Grant
    Filed: July 16, 2012
    Date of Patent: July 22, 2014
    Assignee: Sprout Pharmaceuticals, Inc.
    Inventors: Angelo Ceci, Marcus Schindler
  • Patent number: 8697145
    Abstract: There is provided a method for altering the distribution of body mass by altering the distribution of body mass by decreasing overall percentage fat and/or increasing the proportion of lean mass to fat mass comprising administering to a subject one or more compounds having the ability to alter body mass composition and/or ACE inhibiting activity or a physiologically acceptable derivative or prodrug thereof.
    Type: Grant
    Filed: July 26, 2011
    Date of Patent: April 15, 2014
    Assignee: Horizon Science Pty. Ltd.
    Inventors: David Kannar, Barry James Kitchen, Richard Stuart Weisinger
  • Patent number: 8691976
    Abstract: A low-glycemic available carbohydrate composition of the invention contains the following components: (i) 5-60 wt. % of one or more monosaccharides selected from monosaccharides other than glucose and fructose, in particular galactose, ribose and mannose; (ii) 15-95 wt. % of oligosaccharides having a length of 2 to 20 anhydromonose units, at least half of which are anhydroglucose units linked by non-?-1,4 bonds; these oligosaccharides preferably comprising disaccharides such as palatinose, isomaltose and trehalose and/or non-?-1,4 linked higher glucose-containing oligosaccharides; (iii) 0-45 wt. % of other available carbohydrates, such as glucose and maltodextrins. This carbohydrate composition can be part of a food composition for the treatment of diabetes, obesitas, insulin resistance, or for postprandial glucose response.
    Type: Grant
    Filed: April 2, 2012
    Date of Patent: April 8, 2014
    Assignee: N.V. Nutricia
    Inventors: Katrien Maria Jozefa van Laere, Houkje Bouritius, Mirian Lansink
  • Patent number: 8633175
    Abstract: Novel compounds which are antagonists or inverse agonists at one or more of the opioid receptors, pharmaceutical compositions containing them, to processes for their preparation.
    Type: Grant
    Filed: August 8, 2007
    Date of Patent: January 21, 2014
    Assignee: GlaxoSmithKline LLC
    Inventors: David John Cowan, Andrew Lamont Larkin, Cunyu Zhang, David Lee Musso, Gary Martin Green, Rodolfo Cadilla, Paul Kenneth Spearing, Michael Joseph Bishop, Jason Daniel Speake
  • Patent number: 8623432
    Abstract: Methods of improving a variety of health related factors including, but not limited to weight, cholesterol levels, triglyceride levels and HDL levels, is provided. In one embodiment, a method of reducing body weight in a mammal is provided; the method comprises administering a composition containing an effective amount of Dichrostachys glomerata, to the mammal, whereby the administering of the composition to the mammal is effective in reducing bodyweight in the mammal.
    Type: Grant
    Filed: August 7, 2012
    Date of Patent: January 7, 2014
    Assignee: Gateway Health Alliances, Inc
    Inventor: Julius Enyoug Oben
  • Patent number: 8598120
    Abstract: The present invention relates to novel compounds having a function of a peptide in the amylin family, related nucleic acids, expression constructs, host cells, and processes production of the compounds. The compounds of the invention include one or more amino acid sequence modifications. In addition, methods and compositions are disclosed to treat and prevent metabolic disorders such as obesity, diabetes, and increased cardiovascular risk.
    Type: Grant
    Filed: February 1, 2012
    Date of Patent: December 3, 2013
    Assignees: Amylin Pharmaceuticals, LLC, AstraZeneca Pharmaceuticals LP
    Inventors: Christopher J. Soares, Michael R. Hanley, Diana Y. Lewis, David G. Parkes, Carolyn M. Jodka, Kathryn S. Prickett, Soumitra S. Ghosh, Christine M. Mack, Qing Lin
  • Patent number: 8598153
    Abstract: The present invention relates to natural products that possess fatty acid synthesis inhibitor activity and can be used to treat and prevent diseases such as obesity, cancer, diabetes, fungal infections, Mycobacterium tuberculosis infections, malarial infections and other apicomplexan protozoal diseases.
    Type: Grant
    Filed: March 30, 2012
    Date of Patent: December 3, 2013
    Assignee: Merck Sharp & Dohme Corp.
    Inventors: Sheo B. Singh, Michael R. Tota, Jun Wang
  • Patent number: 8592394
    Abstract: The invention relates to novel synthetic derivatives of ?-glycolipids and uses thereof as immunomodulators. More particularly, the invention relates to synthetic derivatives of ?-glycolipids, specifically, the compounds of any one of Formula I, II III and IV or any mixture or combination thereof, and particularly the ALIB-97 (Formula II) derivative and uses thereof for the treatment of different pathologic disorders, particularly, immune-related hepatic disorders and pathologies associated with the metabolic syndrome.
    Type: Grant
    Filed: October 13, 2009
    Date of Patent: November 26, 2013
    Assignee: Enzo Therapeutics, Inc.
    Inventors: Yaron Ilan, Arie Dagan
  • Patent number: 8586634
    Abstract: The invention relates to protein binding interacting/binding compounds and methods of identifying and using them. The invention further relates to pharmaceutical compositions and methods for treating 5-HT2C disorders, including diseases and disorders mediated by GPCRs.
    Type: Grant
    Filed: June 13, 2008
    Date of Patent: November 19, 2013
    Assignee: University of Florida Research Foundation, Inc.
    Inventor: Raymond G. Booth
  • Patent number: 8586564
    Abstract: The present invention describes compositions and methods for synthetic analogues and derivatives of ?-glycolipids. These analogues and derivatives may be used for the treatment, amelioration or prevention of a pathological disorder. They may also be used for the modulation of the Th1/Th2 cell balance toward an anti-inflammatory or pro-inflammatory response, resulting in the treatment, amelioration or prevention of immune-related disorders.
    Type: Grant
    Filed: September 17, 2009
    Date of Patent: November 19, 2013
    Assignee: Enzo Therapeutics, Inc.
    Inventor: Yaron Ilan
  • Patent number: 8575090
    Abstract: The invention relates to polypeptides comprising an amino acid sequence which is an analogue of pramlintide, pharmaceutical compositions comprising these polypeptides, and these polypeptides for use as medicaments.
    Type: Grant
    Filed: June 8, 2012
    Date of Patent: November 5, 2013
    Assignee: Novo Nordisk A/S
    Inventors: Lauge Schaeffer, Thomas Kruse, Henning Thoegersen
  • Patent number: 8563051
    Abstract: Herbal extracts composition suitable for weight management in mammals is disclosed. The composition comprises a mixture of Garcinia extract, Green tea extract, Green coffee extract and Banaba extract. The method of reducing weight, and treating diabetes in mammals involve oral administration of the composition. The invention further relates to a method of producing and standardizing the individual extract useful for human health.
    Type: Grant
    Filed: December 23, 2011
    Date of Patent: October 22, 2013
    Assignee: InQpharm Sdn Bhd
    Inventors: Philip Samuel, Fred Pescatore
  • Patent number: 8552069
    Abstract: Disclosed is a composition including camphene as an active ingredient for preventing or treating obesity, dyslipidemia, fatty liver or insulin resistance syndrome. The composition of the present disclosure including camphene as an active ingredient suppresses differentiation of adipocytes, reduces body fat, reduces visceral fat, reduces total cholesterol level, reduces serum triglyceride level and reduces liver tissue triglyceride level, and thus exhibits preventive or therapeutic activity for obesity, hyperlipidemia or fatty liver. Furthermore, the composition of the present disclosure exhibits the effect of improving type 2 diabetes or insulin resistance and related metabolic disease by significantly reducing fasting blood sugar level and blood insulin level.
    Type: Grant
    Filed: December 29, 2009
    Date of Patent: October 8, 2013
    Assignee: Industry-Academic Cooperation Foundation, Yonsei University
    Inventor: Tae Sun Park
  • Patent number: 8546378
    Abstract: The present invention relates to a composition comprising phentermine and a selective 5HT-2C receptor agonist. In addition, the invention relates to a composition comprising phentermine and a selective 5HT-2C receptor agonist having Formula (I): or a pharmaceutically acceptable salt, solvate or hydrate thereof. These compositions are useful in pharmaceutical compositions whose use includes the treatment of obesity.
    Type: Grant
    Filed: March 12, 2012
    Date of Patent: October 1, 2013
    Assignee: Arena Pharmaceuticals, Inc.
    Inventors: Dominic P. Behan, Brian M. Smith, Christina Bjenning
  • Patent number: 8541392
    Abstract: The present invention relates generally to a method of blunting the postprandial glycemic response in a human by feeding an induced viscosity fiber system. The invention also relates to an induced viscosity fiber system and the liquid products that incorporate the induced viscosity fiber system. Further, the invention relates to a method of incorporating soluble fiber into a liquid product without the typical negative organoleptic or physical stability issues. The invention also relates to a method of inducing the feeling of fullness and satiety by feeding the induced viscosity fiber system.
    Type: Grant
    Filed: September 30, 2009
    Date of Patent: September 24, 2013
    Assignee: Abbott Laboratories
    Inventors: Bryan W. Wolf, Bruce B. Blidner, Keith A. Garleb, Chron-Si Lai, Timothy W. Schenz
  • Patent number: 8440179
    Abstract: Provide a visceral fat reducing agent for reducing the diseases and conditions associated with the metabolic syndrome which represents a condition where various risk factors such as those for hypertension, hyperlipemia, glucose tolerance dysfunction, etc., have accumulated, or simply reducing an accumulation of visceral fat, wherein the effective ingredient of said visceral fat reducing agent includes fungus bodies of lactic bacteria, especially lactic bacteria belonging to the Lactobacillus sp. and Lactococcus sp. and/or cultures thereof, while also providing a beverage, food or feed containing said visceral fat reducing agent.
    Type: Grant
    Filed: February 29, 2008
    Date of Patent: May 14, 2013
    Assignee: Megmilk Snow Brand Co., Ltd.
    Inventors: Hiroshi Kawakami, Yasuhiko Shiinoki, Yukio Kadooka
  • Patent number: 8440669
    Abstract: The present invention relates to a pharmaceutical composition for the prevention and treatment of diabetes or obesity comprising as active ingredients a compound which inhibits the activity of dipeptidyl peptidase-IV (DPP-IV), a pharmaceutically acceptable salt thereof, a hydrate thereof, or a solvate thereof, and one or more other antidiabetic or antiobesity agents. The pharmaceutical composition exhibits excellent glucose tolerance and may be useful in the prevention and treatment of diabetes, obesity, and the like by effectively inhibiting blood glucose levels and reducing fat mass.
    Type: Grant
    Filed: October 16, 2009
    Date of Patent: May 14, 2013
    Assignee: Dong-A Pharmaceutical Co. Ltd.
    Inventors: Chang Yell Shin, Song-Hyen Choi, Yu Na Chae, Eun Kyoung Yang, Gook Jun Ahn, Moon-Ho Son, Heung Jae Kim, Woo Young Kwak, Jong Pil Min, Tae Hyun Yoon, Soon Hoe Kim, Moohi Yoo
  • Patent number: 8431131
    Abstract: This document provides methods and materials relating to obesity. For example, methods and materials related to treating obesity and identifying agents having the ability to treat obesity are provided.
    Type: Grant
    Filed: February 16, 2012
    Date of Patent: April 30, 2013
    Assignee: Mayo Foundation for Medical Education and Research
    Inventors: Eduardo N. Chini, Maria Thereza P. Barbosa, Sandra M. Soares Herrmann
  • Patent number: 8425914
    Abstract: Compositions and methods are provided for treatment growth hormone and/or insulin-like growth factor 1 deficiency in a patient in need of such treatment. Compositions and methods include novel vaccines that provide immunogenicity for somatostatin and result in the increased release of endogenously produced growth hormone and/or insulin-like growth factor 1.
    Type: Grant
    Filed: June 24, 2009
    Date of Patent: April 23, 2013
    Assignee: Braasch Biotech LLC
    Inventors: Keith N. Haffer, James Larrick, Andrew R. Mendelsohn
  • Patent number: 8399474
    Abstract: The present invention relates to methods of treating metabolic syndrome, Type 2 diabetes mellitus, atherogenic dyslipidemia and/or obesity. The present invention also relates to methods of restoring the incretin effect, to restoring physiologic control of glucagon levels, to restoring first-phase insulin secretion, and to restoring the physiologic glucose-dependent insulin secretion. The methods of the present invention comprise administration of a selective ?-receptor antagonist, such as guanidinylated naltrindole (GNTI), or pharmaceutically acceptable derivatives thereof to a subject in need thereof.
    Type: Grant
    Filed: October 18, 2010
    Date of Patent: March 19, 2013
    Assignee: Neurendo Pharma, LLC
    Inventor: Anton H. Clemens
  • Patent number: 8394432
    Abstract: Methods of improving a variety of health related factors including, but not limited to weight, cholesterol levels, triglyceride levels and HDL levels, is provided. In one embodiment, a method of reducing body weight in a mammal is provided; the method comprises administering a composition containing an effective amount of Xylopia aethiopica, to the mammal, whereby the administering of the composition to the mammal is effective in reducing bodyweight in the mammal.
    Type: Grant
    Filed: July 24, 2012
    Date of Patent: March 12, 2013
    Assignee: Gateway Health Alliances, Inc.
    Inventor: Julius Enyoug Oben
  • Patent number: 8394860
    Abstract: The present invention relates generally to methods and related compositions using flavonoids and/or indanes extracted from the stems and leaves of C. quadrangularis to reduce weight and inhibit lipase, ?-amylase and ?-glucosidase activity in mammals. By example and not by way of limitation, embodiments of the present disclosure, a composition and related methods for reducing body weight and/or inhibiting any combination of lipase, ?-amylase and ?-glucosidase is provided. The composition contains an effective amount of one or more flavonoids or indanes selected from 3-O-rhamnopyranosylkaempferol, 3-(4-hydroxybenzylidene)-2-(2,5-dihydroxyphenyl)-1-(4-hydroxyphenyl)indane-4,6-diol, quercitrin, rhamnitrin, rhamnocitrin, quercitrin-3-O?-acetate and parthenocissin A.
    Type: Grant
    Filed: January 12, 2010
    Date of Patent: March 12, 2013
    Assignee: Gateway Health Alliances, Inc.
    Inventor: Julius Enyong Oben
  • Patent number: 8362090
    Abstract: The present invention relates generally to methods and related compositions using flavonoids and/or indanes extracted from the stems and leaves of C. quadrangularis to reduce weight and inhibit lipase, ?-amylase and ?-glucosidase activity in mammals. By example and not by way of limitation, embodiments of the present disclosure, a composition and related methods for reducing body weight and/or inhibiting any combination of lipase, ?-amylase and ?-glucosidase is provided. The composition contains an effective amount of one or more flavonoids or indanes selected from 3-O-rhamnopyranosylkaempferol, 3-(4-hydroxybenzylidene)-2-(2,5-dihydroxyphenyl)-1-(4-hydroxyphenyl)indane-4,6-diol, quercitrin, rhamnitrin, rhamnocitrin, quercitrin-3-O?-acetate and parthenocissin A.
    Type: Grant
    Filed: January 12, 2010
    Date of Patent: January 29, 2013
    Assignee: Gateway Health Alliances, Inc.
    Inventor: Julius Enyong Oben
  • Patent number: 8361523
    Abstract: Methods of improving a variety of health related factors including, but not limited to weight, cholesterol levels, triglyceride levels and HDL levels, is provided. In one embodiment, a method of reducing body weight in an overweight subject is provided; the method comprises administering a composition containing an effective amount of Hypodaphnis zenkeri, to an overweight subject, whereby the administering of the composition to the overweight subject is effective in reducing bodyweight in the overweight subject.
    Type: Grant
    Filed: July 24, 2012
    Date of Patent: January 29, 2013
    Assignee: Gateway Health Alliances, Inc.
    Inventor: Julius Enyoug Oben
  • Patent number: 8343985
    Abstract: The present invention relates to compounds and pharmaceutically acceptable salts thereof and formulations comprising the compounds or a pharmaceutically acceptable salts thereof that are useful in modulating lyn kinase activity. In particular, the compounds or a pharmaceutically acceptable salts thereof are useful for treating or preventing a disease or disorder including cardiovascular disease, dyslipidemia, dyslipoproteinemia, a disorder of glucose metabolism, metabolic syndrome (i.e., Syndrome X), a peroxisome proliferator activated receptor-associated disorder, septicemia, a thrombotic disorder, type II diabetes, obesity, pancreatitis, hypertension, renal disease, inflammation, or impotence.
    Type: Grant
    Filed: July 15, 2010
    Date of Patent: January 1, 2013
    Assignee: Melior Pharmaceuticals I, Inc.
    Inventors: Andrew Reaume, Michael S. Saporito
  • Patent number: 8338394
    Abstract: A pharmaceutical composition for treating a metabolic disease in a mammalian subject includes a therapeutically effective amount of all-trans-13,14-dihydroretinoid, all-trans-13,14-dihydroretinoid derivative, or agent capable of modulating the level of at least one all-trans-13,14-dihydroretinoid or all-trans-13,14-dihydroretinoid derivative in the subject.
    Type: Grant
    Filed: October 9, 2007
    Date of Patent: December 25, 2012
    Assignee: Case Western Reserve University
    Inventors: Krzysztof Palczewski, Radu A. Moise
  • Patent number: 8318213
    Abstract: A composition comprising an effective amount of Cissus quadrangularis to reduce fat and cause weight loss in a mammal. Such compositions have beneficial activity principally in controlling weight gain and obesity.
    Type: Grant
    Filed: July 16, 2009
    Date of Patent: November 27, 2012
    Assignee: Gateway Health Alliances, Inc.
    Inventor: Julius Enyong Oben
  • Patent number: 8304448
    Abstract: Disclosed is a composition for the prevention and treatment of metabolic diseases, which comprises a benzazole derivative as an active ingredient. The benzazole derivative has inhibitory activity against DGAT (diacylglycerol acyltransferase), which causes metabolic diseases such as obesity and diabetes in the process of lipid metabolism. With the ability to effectively control lipid metabolism and energy metabolism, thus, the composition is useful in the prevention and treatment of metabolic diseases, such as obesity and diabetes.
    Type: Grant
    Filed: September 27, 2007
    Date of Patent: November 6, 2012
    Assignee: Korea Research Institute of Bioscience and Biotechnology
    Inventors: Hyun Sun Lee, Kyeong Lee, Jung Joon Lee, Young Kook Kim, Mun-Chual Rho, Jeong Hyung Lee, Young Soo Hong, Hye-Ran Park, Chul-Ho Lee, Yongseok Choi
  • Patent number: 8252312
    Abstract: The present invention provides an oral solid composition comprising a lipase inhibitor, an acid soluble polymer and an excipient. The composition may further comprise a second active. The composition may also further comprise a functional excipient.
    Type: Grant
    Filed: December 27, 2011
    Date of Patent: August 28, 2012
    Inventors: David Wong, Kate Wensie Wong, Spencer Wenyen Wong
  • Patent number: 8241682
    Abstract: Methods of improving a variety of health related factors including, but not limited to weight, cholesterol levels, triglyceride levels and HDL levels, is provided. In one embodiment, a method of reducing LDL cholesterol levels of a mammal in need thereof is provided, the method comprises administering a composition containing an effective amount of Dichrostachys glomerata, to a mammal, whereby the administering of the composition to the mammal is effective in reducing LDL cholesterol levels in the mammal.
    Type: Grant
    Filed: October 8, 2010
    Date of Patent: August 14, 2012
    Assignee: Gateway Health Alliances, Inc.
    Inventor: Julius E. Oben
  • Patent number: 8242180
    Abstract: Low sugar solid food product such as a cracker, chip, shelf-stable bread or crouton, that promotes satiety primarily as a result of its high fiber and protein content. The fiber plus protein content, expressed in grams, times n=kcal per portion, where n is from 5 to 10 gives a result from 1 to 3.
    Type: Grant
    Filed: October 20, 2008
    Date of Patent: August 14, 2012
    Assignee: Susan B. Roberts, LLC
    Inventor: Susan B. Roberts
  • Patent number: 8242171
    Abstract: Provided herein are methods and compositions for modulating the activity or level of a sirtuin, thereby treating or preventing obesity or an insulin resistance disorder, such as diabetes in a subject. Exemplary methods comprise contacting a cell with a sirtuin activating compound or an inhibitory compound to thereby increase or decrease fat accumulation, respectively.
    Type: Grant
    Filed: January 7, 2010
    Date of Patent: August 14, 2012
    Assignees: President and Fellows of Harvard College, The General Hospital Corporation
    Inventors: David A. Sinclair, Maria Alexander-Bridges
  • Patent number: 8236359
    Abstract: For reducing the negative effects of the metabolic syndrome on mammal organisms, it is proposed to use phytoecdysones for diminishing the fat body mass in individuals, notably with a weight excess. Phytoecdysones are advantageously incorporated into a food composition. The phytoecdysones can come from food plants, such as quinoa.
    Type: Grant
    Filed: November 19, 2008
    Date of Patent: August 7, 2012
    Assignees: Institut Biophytis SAS, Universite Pierre et Marie Curie, Centre National de la Recherche Scientifique (CNRS)
    Inventors: Stanislas Veillet, Rene Lafont
  • Patent number: 8227476
    Abstract: The invention relates to a method for the treatment of obesity and related diseases comprising the administration of a therapeutically effective amount of Flibanserin.
    Type: Grant
    Filed: July 31, 2006
    Date of Patent: July 24, 2012
    Assignee: Sprout Pharmaceuticals, Inc.
    Inventors: Angelo Ceci, Marcus Schindler
  • Patent number: 8207185
    Abstract: A method of treating a condition in a subject in need thereof, comprising administering a calcium/calmodulin dependency kinase kinase (CaMKK) inhibitor in a treatment-effective amount. Conditions which may be treated include obesity (particularly adult obesity), insulin resistance (including high fat diet-induced insulin resistance), hyperglycemia (including hyperglycemia accompanying obesity), diabetes, etc.
    Type: Grant
    Filed: October 4, 2007
    Date of Patent: June 26, 2012
    Assignee: Duke University
    Inventor: Anthony R. Means
  • Patent number: 8198260
    Abstract: A composition is disclosed suitable for the prevention and/or treatment of disorders due to abnormal lipid metabolism, such as hypercholesterolaemia, atherosclerosis, hyperlipidaemia and obesity, and which can therefore take the form of a dietary supplement or of an actual medicine, comprising as characterizing active ingredients: (a) propionyl L-carnitine or a pharmacologically acceptable salt thereof, and (b) chitosan or its derivatives and congeners.
    Type: Grant
    Filed: June 9, 2004
    Date of Patent: June 12, 2012
    Assignee: Sigma-Tau Industrie Farmaceutiche Riunite SpA
    Inventor: Claudio Cavazza
  • Patent number: 8197860
    Abstract: The present application relates to a method for enhancing absorption of a nutrient in a subject in need thereof with an effective amount of an isolated astragaloside compound.
    Type: Grant
    Filed: April 15, 2009
    Date of Patent: June 12, 2012
    Assignee: Nuliv Holding Inc.
    Inventors: Hang-Ching Lin, Wen-Liang Chang, Tsu-Chung Chang, Hsiou-Yu Ding, Tian Shung Wu
  • Patent number: 8148350
    Abstract: A low-glycemic available carbohydrate composition of the invention contains the following components: (i) 5-60 wt. % of one or more monosaccharides selected from monosaccharides other than glucose and fructose, in particular galactose, ribose and mannose; (ii) 15-95 wt. % of oligosaccharides having a length of 2 to 20 anhydromonose units, at least half of which are anhydroglucose units linked by non-?-1,4 bonds; these oligosaccharides preferably comprising disaccharides such as palatinose, isomaltose and trehalose and/or non-?-1,4 linked higher glucose-containing oligosaccharides; (iii) 0-45 wt. % of other available carbohydrates, such as glucose and maltodextrins. This carbohydrate composition can be part of a food composition for the treatment of diabetes, obesitas, insulin resistance, or for postprandial glucose response.
    Type: Grant
    Filed: December 20, 2006
    Date of Patent: April 3, 2012
    Assignee: N.V. Nutricia
    Inventors: Katrien Maria Jozefa van Laere, Houkje Bouritius, Mirian Lansink
  • Patent number: 8143014
    Abstract: This document provides methods and materials relating to obesity. For example, methods and materials related to treating obesity and identifying agents having the ability to treat obesity are provided.
    Type: Grant
    Filed: October 2, 2008
    Date of Patent: March 27, 2012
    Assignee: Mayo Foundation for Medical Education and Research
    Inventors: Eduardo N. Chini, Maria Thereza P. Barbosa, Sandra M. Soares
  • Patent number: 8114958
    Abstract: The present invention relates to obesity related polypeptides (ORPs), related nucleic acids, expression constructs, host cells, and processes production of the obesity related polypeptides. The ORPs of the invention include one or more amino acid sequence modifications. In addition, methods and compositions are disclosed to treat and prevent metabolic disorders such as obesity, diabetes, and increased cardiovascular risk.
    Type: Grant
    Filed: February 11, 2005
    Date of Patent: February 14, 2012
    Assignee: Amylin Pharmaceuticals, Inc.
    Inventors: Christopher J. Soares, Michael R. Hanley, Diana Y. Lewis, David Geoffrey Parkes, Carolyn M. Jodka, Kathryn S. Prickett, Soumitra S. Ghosh, Christine Marie Mack, Qing Lin
  • Patent number: 8114911
    Abstract: Provided is a composition for treating obesity which comprises an effective amount of a prostaglandin compound, especially, a compound of formula (I).
    Type: Grant
    Filed: October 22, 2003
    Date of Patent: February 14, 2012
    Assignee: Sucampo AG
    Inventor: Ryuji Ueno
  • Patent number: 8110186
    Abstract: A method to effectively treat the adverse events of ingested orlistat, and to maintain the effectiveness of ingested orlistat, the method comprising the steps of: ingesting a compound of orlistat to irreversibly bind with lipase enzymes of the gastrointestinal tract; ingesting a compound of simethicone to cause undigested fats to remain in an emulsified state in the bowel; and ingesting an enteric coated activated charcoal member to absorb emulsified fats only in the lower bowel, thus preventing the adverse events associated with the ingestion of orlistat alone.
    Type: Grant
    Filed: February 8, 2010
    Date of Patent: February 7, 2012
    Assignee: Chelatexx, LLC
    Inventor: Ronald J. Thompson